2000
DOI: 10.1016/s0264-410x(00)00171-7
|View full text |Cite
|
Sign up to set email alerts
|

Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
23
0

Year Published

2001
2001
2018
2018

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 78 publications
(23 citation statements)
references
References 38 publications
0
23
0
Order By: Relevance
“…Oil-inwater nanoemulsion systems have an excellent safety profile and are widely used as clinical vaccine adjuvants (26)(27)(28)(29)(30). We reported previously that intraperitoneally injected Clec9A-TNE, grafted with immune-evading polymer PEG and anti-Clec9A mAb using a noncovalent click self-assembly, evaded nonspecific phagocytosis and clearance and targeted antigen to CD8 + DCs in mice.…”
Section: Resultsmentioning
confidence: 99%
“…Oil-inwater nanoemulsion systems have an excellent safety profile and are widely used as clinical vaccine adjuvants (26)(27)(28)(29)(30). We reported previously that intraperitoneally injected Clec9A-TNE, grafted with immune-evading polymer PEG and anti-Clec9A mAb using a noncovalent click self-assembly, evaded nonspecific phagocytosis and clearance and targeted antigen to CD8 + DCs in mice.…”
Section: Resultsmentioning
confidence: 99%
“…It was surprising that none of the adjuvanted formulations had any greater effect than that of the simple formulation containing inactivated virus in saline, although it is in consistence with the observations by others. 25 A clinical clue for a mucoadhesive effect of the thixotropic substance was in fact registered since none of the volunteers receiving that particular formulation complained about having had a runny nose. Possibly, the need for such adjuvants in this study may have been masked by the many intranasal immunizations and the large doses used.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, one of our next goals is to identify a mucosal adjuvant that could be used safely and economically in humans. Although mucosal adjuvants have been tested in humans in conjunction with various vaccines (3,(12)(13)(14)(15), it is unclear whether these would be effective with our killed pneumococcal preparation. Thus, our approach may have immunological advantages and drawbacks that must be further examined.…”
Section: Discussionmentioning
confidence: 99%